



RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

1645

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Clifford P. Stanners et al.

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

Docket No.: 186.009US1

Serial No.: 09/637,530

Filed: August 11, 2000

Due Date: August 11, 2001

Examiner: Unknown

Group Art Unit: 1645

Commissioner for Patents
Washington, D.C. 20231

We are transmitting herewith the following attached items (as indicated with an "X"):

☒ A return postcard.

☒ An Information Disclosure Statement (1 p.), Form 1449 (2 p.), and copies of 13 cited references.

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By: Ann M. McCrackin
Atty: Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 18 day of July, 2001.

ANN MCCRACKIN
Name


Ann M. McCrackin
Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

(GENERAL)



09/637,530

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

Applicant: Clifford P. Stanners et al.

Examiner: Unknown

Serial No.: 09/637,530

Group Art Unit: 1645

Filed: August 11, 2000

Docket: 186.009US1

Title: CEA/NCA-BASED DIFFERENTIATION CANCER THERAPY

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicants respectfully request that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicants further request that a copy of the 1449 form, initialled by the Examiner to indicate that all listed citations have been considered, be returned with the next official communication.

Under 37 C.F.R. §1.97(b)(3), it is believed that no fee or certificate is required with this Information Disclosure Statement. However, if an Office Action on the merits has been mailed, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Account No. 19-0743.

The Examiner is invited to contact the Applicants' Representatives at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,

CLIFFORD P. STANNERS ET AL.

By their Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938
Minneapolis, MN 55402
(612) 349-9592

Date July 18, 2001

By Ann M. McCrackin

Ann M. McCrackin
Reg. No. 42,858

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 18 day of July, 2001.

ANN MCCRAKIN
Name

Ann M. McCrackin
Signature

RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

Sheet 1 of 2

Form 1449*

Atty. Docket No.: 186.009US1

Serial No. 09/637,530

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Applicant: Clifford P. Stanners et al.

Filing Date: August 11, 2000

Group: 1645

U.S. PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
-----------------------	-----------------	------	------	-------	----------	-------------------------------

FOREIGN PATENT DOCUMENTS

**Examiner Initial	Document Number	Date	Country	Class	Subclass	Translation Yes No
	0584368	03/02/1994	European	C12P	21/08	
	97/34638	09/25/1997	PCT	A61K	48/00	

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner Initial	
	Benchimol, S., et al., "Carcinoembryonic Antigen, a Human Tumor Marker, Functions as an Intercellular Adhesion Molecule", <u>Cell</u> , 57, pp. 327-334, (April 21, 1989)
	Eidelman, F.J., et al., "Human Carcinoembryonic Antigen, an Intercellular Adhesion Molecule, Blocks Fusion and Differentiation of Rat Myoblasts", <u>The Journal of Cell Biology</u> , 123 (2), pp. 467-475, (Oct. 1993)
	Hashino, J., et al., "Production and Characterization of Monoclonal Antibodies to N-Domain and Domain III of Carcinoembryonic Antigen", <u>Biochemical and Biophysical Research Communication</u> , 197 (2), pp. 886-893, (Dec. 15, 1993)
	Ilantzis, C., et al., "A Colonic Tissue Architecture Assay Applied to Human Colon Carcinoma Cells", <u>In Vitro Cell. Dev. Biol.---Animal</u> , 33, pp. 50-61, (Jan. 1997)
	Ilantzis, C., et al., "Cell-Surface Levels of Human Carcinoembryonic Antigen Are Inversely Correlated with Colonocyte Differentiation in Colon Carcinogenesis", <u>Laboratory Investigation</u> , 76 (5), pp. 703-716, (1997)
	Rojas, M., et al., "Radical Differences in Function of Closely Related Members of the Human Carcinoembryonic Antigen Gene Family", <u>Cell Growth & Differentiation</u> , 7, pp. 655-662, (May 1996)
	Screaton, R.A., et al., "Carcinoembryonic Antigen, a Human Tumor Marker, Cooperates with Myc and Bcl-2 in Cellular Transformation", <u>The Journal of Cell Biology</u> , 137 (4), pp. 939-952, (May 19, 1997)
	Stanners, C.P., et al., "Opposite Functions for Two Classes of Genes of the Human Carcinoembryonic Antigen Family", <u>Tumor Biol.</u> , 16, pp. 23-31, (1995)

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

AUG 01 2001

TECH CENTER 1600/2900

Sheet 2 of 2

Form 1449*

Atty. Docket No.: 186.009US1

Serial No. 09/637,530

INFORMATION DISCLOSURE STATEMENT
BY APPLICANT
(Use several sheets if necessary)

Applicant: Clifford P. Stanners et al.

Filing Date: August 11, 2000

Group: 1645

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

**Examiner
Initial

Stocks, S.C., et al., "CD66-dependent neutrophil activation: a possible mechanism for vascular selectin-mediated regulation of neutrophil adhesion", Journal of Leukocyte Biology, 58, pp. 40-48, (July 1995)

Zhou, H., et al., "Specificity of Anti-Carcinoembryonic Antigen Monoclonal Antibodies and Their Effects on CEA-Mediated Adhesion", Cancer Research, 53, pp. 3817-3822, (Aug. 15, 1993)

Zhou, H., et al., "Specificity of Intercellular Adhesion Mediated by Various Members of the Immunoglobulin Supergene Family", Cell Growth & Differentiation, 1 (5), pp. 209-215, (May 1990)

Examiner

Date Considered

*Substitute Disclosure Statement Form (PTO-1449)

**EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.